Trial
NCT01574222
A Vaccine Trial for Patients With Stage IIIB, IV, or Recurrent Non-Small Cell Lung Cancer
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
VA Office of Research and Development
Collaborators
Jonsson Comprehensive Cancer Center; National Cancer Institute (NCI)
Condition
Non-Small Cell Lung Cancer (NSCLC)
Intervention
autologous dendritic cell adenovirus CCL21 vaccine
Why stopped
Estimated Primary Completion Date: March 2017 (Final data collection date for primary outcome measure)
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-01-18